Why Germany’s Drug Prices Cause a Trade Showdown with the US

The US is questioning how Germany pays for new medicines. It started an official review under trade rules that let countries challenge unfair pricing. The focus is on whether Germany keeps cutting payments for breakthrough drugs in ways that hurt US companies. Officials worry Germany might speed up plans to slash drug costs even more. They argue this could block fair profits for foreign drugmakers. The US Trade Representative didn’t hold back, calling the moves unreasonable and unfair to innovation.

Germany hasn’t answered yet, but the debate isn’t new. Countries have long argued over how much health systems should pay for life-saving medicines. The US sees this as a trade issue, while Germany likely sees it as a way to keep healthcare affordable. Public comments will open soon, and a hearing is planned for later this year. The outcome could reshape how drug prices are set globally, making it a high-stakes fight for both sides.

Actions